Bayer Reshapes Pharmaceutical Division Leadership to Fuel Growth
By Andrea Figueras
Bayer streamlined the leadership team of its pharmaceutical division in a move to boost growth.
Sebastian Guth will take new role of chief operating officer, effective from April 1. He will be responsible for the commercial operations of all markets in which the company is active, the German pharmaceutical and agricultural conglomerate said Wednesday.
The division is focusing on renewing its top line, growing its portfolio value and leveraging a new operating model, with the aim of becoming a growth driver for the company, Bayer said.
The company also created a new organization called global commercialization, which will be headed by Christine Roth as of June 1.
The organization comprises parts of the former Oncology, Global Marketing and Digital & Commercial Innovation business unit as well as parts of Medical Affairs & Pharmacovigilance.
"These changes within our leadership team reflect this new approach to realize the full potential of our growth opportunities," member of the management board and president of the pharmaceuticals division Stefan Oelrich said.
Bayer has been striving to cut debt and lift its beleaguered share price. Investors have pressured the company to spin off, as its three units--crop science, consumer health and pharmaceuticals--are highly diversified.
Earlier this month, the company said it wasn't planning to split into separate units for the time being and that it intended to focus on building a strong pharmaceuticals pipeline, addressing litigation, reducing debt, and continuing to implement its new operating model.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
March 20, 2024 08:28 ET (12:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase